Two items which I find represent the good and the bad with Daybue revenue from the latest update: 1.80% of payers have written policies in place with ~90% conversion to paid over time. This suggests that the level of evidence provided by the company and doctors is satisfying payers as to the level of health economic value provided by the drug.
2.Q1 2024 862 patients on therapy from 1250 patient commencements. Q2 2024 900 patients on therapy from 1500 patient commencements[30% of 5000]. The net increase in patients for 3 months quarter to quarter was 38 patients from 250 commencements and reveal a retention rate of 15.2%. Neuren described the momentum from Q2 2024 as encouraging yet these figures appear to be anything but encouraging. Kens
NEU Price at posting:
$17.09 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)